Malignancies
Showing 1 - 25 of 6,741
Prevelance Of Cutaneous Disorders Among Heamatologic
Not yet recruiting
- Dermatologic Disorders With Heamatologic Malignancies Patients
- cbc ,u\s renalor hepatic function test if needed
-
Sohag, EgyptSohag university Hospital
Oct 25, 2023
Quality of Life After Gynacological Malignancies
Not yet recruiting
- Gynecologic Cancer
- Evaluate quality of life after gynaecological malignancies diagnosis and treatment
- (no location specified)
Jan 11, 2023
CAR-T Treatment for Hematological Malignancies
Recruiting
- Hematological Malignancies
- Chimeric Antigen Receptor T-cell Therapy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 11, 2023
Immunotherapy-related CRP Kinetics in Metastatic Gynecological
Recruiting
- Gynecological Malignancies
- +4 more
-
Tuebingen, GermanyDepartment of Women's Health
Jun 13, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Advanced Malignancies Trial in Guangzhou (BRY812 for injection)
Not yet recruiting
- Advanced Malignancies
- BRY812 for injection
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital,Sun Yat-sen University
Sep 7, 2023
Hematological Malignancies Trial in Limoges ("Blend of ginger and lemon essential oils", "Neutral oil")
Not yet recruiting
- Hematological Malignancies
- "Blend of ginger and lemon essential oils", "Neutral oil"
-
Limoges, FranceUniversity Hospital, Limoges
Nov 20, 2023
Gynecological Malignancies Trial in Beijing (BL-M07D1)
Not yet recruiting
- Gynecological Malignancies
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Nov 15, 2023
Myeloid Malignancies Trial in Chendu (fractionated busulfan-based conditioning regimen)
Recruiting
- Myeloid Malignancies
- fractionated busulfan-based conditioning regimen
-
Chendu, Sichuan, ChinaWest China Hospital, Sichuan University
Mar 29, 2023
Solid Malignancies Trial (Tisotumab Vedotin)
Not yet recruiting
- Solid Malignancies
- Tisotumab Vedotin
- (no location specified)
May 9, 2023
Relapsed/Refractory B-cell Malignancies Trial (AC676)
Not yet recruiting
- Relapsed/Refractory B-cell Malignancies
- (no location specified)
Mar 27, 2023
Gynaecological Malignancies Trial (SHR- A1811)
Not yet recruiting
- Gynaecological Malignancies
- SHR- A1811
- (no location specified)
Jun 8, 2023
Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement
Recruiting
- Lymphoma
- +4 more
- Vysis LSI MYC Break Apart Rearrangement Probe Kit
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)
Not yet recruiting
- Relapsed/Refractory Aggressive B-Cell Malignancies
- ONCT-808
- Bridging Therapy
- (no location specified)
Jan 19, 2023
B-Cell Malignancies Trial (TT-01488 Tablets)
Not yet recruiting
- B-Cell Malignancies
- TT-01488 Tablets
- (no location specified)
Jan 4, 2023
Hematological Malignancies Trial in Tianjin (ICP-248)
Not yet recruiting
- Hematological Malignancies
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023
Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)
Recruiting
- Hematologic Malignancies
- RD13-02 cell infusion
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jun 26, 2023
Relmacabtagene Autoleucel in Hematologic Malignancies
Not yet recruiting
- Lymphoma, B-Cell
- +2 more
- Relmacabtagene Autoleucel
-
Beijing, Beijing, China
- +1 more
Nov 15, 2023
Chemo-induced Thrombocytopenia Trial (Hetrombopag)
Not yet recruiting
- Chemotherapy-induced Thrombocytopenia
- (no location specified)
Oct 20, 2023
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Advanced Malignant Cancer Trial (HRS-7053 Injection)
Not yet recruiting
- Advanced Malignant Cancer
- HRS-7053 Injection
- (no location specified)
Aug 7, 2023